CD274 and neoplasm: After these preliminary results of anti-PD-(L)1 monotherapy, and given the premise that combining chemotherapy with immunotherapy might further enhance tumor antigenicity, ES-SCLC has also been hit by the current wave of combination strategies, leading to a substantial change in the first-line setting.